Everolimus-Eluting Platinum Chromium Coronary Stent System
The SYNERGY Stent is designed so its attributes synergistically work together to promote optimal healing within the vessel.1
Synchrony™ Bioabsorbable Polymer Coating is applied only to the abluminal side of the stent to stimulate healthy endothelialization.1 The polymer is gone when it’s no longer needed, shortly after the drug is completely eluted at three months, which minimizes polymer exposure in the vessel.1, 2
Lower Inflammation Rates3
In a preclinical model, SYNERGYTM BP Stent demonstrated:
- Significantly reduced Early Inflammation versus Bare Metal Stents (BMS)
- Significantly reduced Late Inflammation versus Permanent Polymer (PP) Stents
Not All Bioabsorbable Polymer Stents are Created Equal
BP Stents differ in terms of polymer application, polymer type, polymer absorption time, drug type, drug elution times and stent design.
Optimal Healing Shown Through Strut Coverage and Angioscopy
SYNERGY BP Stent has shown full stent strut coverage as early as 30-days in humans and showed 0% stent thrombosis in all of these OCT analyses.6
Leading on Studying Short DAPT
Supporting well-constructed prospective Short DAPT clinical trials with over 5,000 patients to study the SYNERGY™ BP Stent in different complex patient populations.
The SYNERGY BP Stent was intentionally designed with a fast-absorbing polymer
to enable short DAPT.†
* Investigator Sponsored Study. Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which
is the sole responsibility of the investigators. Boston Scientific’s involvement in investigator-sponsored research is limited to providing financial support for research
that advances medical and scientific knowledge about our products.
SENIOR Trial: Safety Data at 2-Years
The SYNERGY™ BP Stent continued to show superior results versus REBEL™ BMS with short BMS-like DAPT regimen at 2-years.
SENIOR Trial: Safety and Primary Endpoint Data at 1-Year
The SYNERGY BP Stent showed significantly lower MACCE** rates versus REBEL BMS at 1-year.